Cabometyx

EU approves Cabometyx (cabozantinib) for advanced kidney cancer

By Sharon Kell|2016-09-15T07:41:59+00:0015 Sep 2016|Drug treatments|

The European Medicines Agency (EMA) has approved Cabometyx (cabozantinib) as [...]

Comments Off

Cabozantinib and lenvatinib recommended for approval by the EMA

By Sharon Kell|2016-07-26T15:55:51+00:0026 Jul 2016|Drug treatments|

Cabozantinib (Cabometyx, Ipsen Pharma) and lenvatinib (Kisplyx, Eisai Europe Ltd) [...]

Comments Off

Cabozantinib extends survival in advanced kidney cancer compared to axitinib

By Sharon Kell|2016-06-14T14:25:04+00:0014 Jun 2016|Drug treatments|

Results from the phase III METEOR clinical trial, which compares [...]

Comments Off

Cabozantinib improves progression-free survival in renal cell carcinoma

By Sharon Kell|2016-05-24T15:01:02+00:0024 May 2016|Drug treatments|

Results from the phase II CABOSUN trial, released this week, [...]

Comments Off

Cabozantinib receives FDA approval for kidney cancer

By Sharon Kell|2016-05-05T08:30:41+00:005 May 2016|Drug treatments|

Exelixis has announced that the US Food and Drug Administration [...]

Comments Off

Address

Action Kidney Cancer

11th Floor
3 Piccadilly Place
Manchester M1 3BN

Helpline

0800 121 8721
Email Us

About Action Kidney Cancer

We are the UK’s largest and most active patient-led kidney cancer charity. Whether you are a patient, survivor or someone you know has been diagnosed with kidney cancer, you have come to the right place to find support and information, and to be part of a caring and knowledgeable community of people: We are here to help you.

Registered charity in England, Wales (1164238), and Scotland (SC051330).

© Copyright Action Kidney Cancer 2021

Links

Branding by Kingswood Marketing

Policies

Website Policies

Complaints Policy

Equal Opportunities Policy

Information Governance Policy

Social Media Policy

Health Information Policy

Follow

Our Website Design Specialist | Douglass Digital

Helpline: 0800 121 8721

support@actionkidneycancer.org